Your browser doesn't support javascript.
loading
[Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration]. / Erste Erfahrungen mit Brolucizumab bei neovaskulärer altersabhängiger Makuladegeneration und Therapierefraktärität unter der bisherigen Anti-VEGF-Therapie.
Book, Marius; Ziegler, M; Rothaus, K; Faatz, H; Gutfleisch, M; Spital, G; Lommatzsch, A; Pauleikhoff, D.
Affiliation
  • Book M; Augenzentrum am St. Franziskus-Hospital, Münster, Deutschland. marius.book@augen-franziskus.de.
  • Ziegler M; Augenzentrum am St. Franziskus-Hospital, Münster, Deutschland.
  • Rothaus K; Augenzentrum am St. Franziskus-Hospital, Münster, Deutschland.
  • Faatz H; Augenzentrum am St. Franziskus-Hospital, Münster, Deutschland.
  • Gutfleisch M; Augenzentrum am St. Franziskus-Hospital, Münster, Deutschland.
  • Spital G; Augenzentrum am St. Franziskus-Hospital, Münster, Deutschland.
  • Lommatzsch A; Augenzentrum am St. Franziskus-Hospital, Münster, Deutschland.
  • Pauleikhoff D; Klinik für Augenheilkunde, Universitätsklinikum Essen, Essen, Deutschland.
Ophthalmologe ; 119(3): 258-264, 2022 Mar.
Article in De | MEDLINE | ID: mdl-34351479
ABSTRACT

BACKGROUND:

Pivotal clinical trials have proven brolucizumab to be a potent intravitreal anti-vascular endothelial growth factor (VEGF) drug in patients with neovascular age-related macular degeneration (nAMD). Therefore, it seems to be a promising drug also in patients with recalcitrant nAMD. This article presents the results of patients who were switched to brolucizumab due to persistent fluid under previous anti-VEGF treatment.

METHODS:

In this study 21 eyes were retrospectively analyzed in which treatment was switched to brolucizumab due to persistent intraretinal (IRF), subretinal (SRF) and/or sub-retinal pigment epithelium (sub-RPE fluid) fluid despite long-term anti-VEGF treatment. Functional and spectral domain optical coherence tomography (SD-OCT) data were investigated at diagnosis of nAMD (I), at switch to brolucizumab (II), 4 weeks after upload of brolucizumab (III) and at first reactivation of macular neovascularization (MNV, IV).

RESULTS:

There were no significant changes in fluid distribution between (I) and (II). After upload of brolucizumab (III) a significant reduction of central subfield retinal thickness (CSRT, p = 0.0001), SRF (p = 0.004) and sub-RPE fluid (p = 0.04), but no visual acuity improvement (p = 0.56) were observed.

CONCLUSION:

Intravitreal brolucizumab treatment can achieve significant reductions particularly of SRF and sub-RPE in patients refractory to previous anti-VEGF treatment. Future studies should further investigate the effects of brolucizumab in patients with recalcitrant nAMD.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Wet Macular Degeneration / Macular Degeneration Type of study: Diagnostic_studies / Observational_studies Limits: Humans Language: De Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Main subject: Wet Macular Degeneration / Macular Degeneration Type of study: Diagnostic_studies / Observational_studies Limits: Humans Language: De Year: 2022 Type: Article